DE60144376D1 - N und anwendungen - Google Patents

N und anwendungen

Info

Publication number
DE60144376D1
DE60144376D1 DE60144376T DE60144376T DE60144376D1 DE 60144376 D1 DE60144376 D1 DE 60144376D1 DE 60144376 T DE60144376 T DE 60144376T DE 60144376 T DE60144376 T DE 60144376T DE 60144376 D1 DE60144376 D1 DE 60144376D1
Authority
DE
Germany
Prior art keywords
aryl
alkyl
alkenyl
present
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144376T
Other languages
German (de)
English (en)
Inventor
Michael R Boyd
Kirk R Gustafson
Charles L Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Application granted granted Critical
Publication of DE60144376D1 publication Critical patent/DE60144376D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DE60144376T 2000-07-24 2001-07-24 N und anwendungen Expired - Lifetime DE60144376D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22027000P 2000-07-24 2000-07-24
PCT/US2001/023633 WO2002008231A2 (en) 2000-07-24 2001-07-24 Biologically active macrolides, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
DE60144376D1 true DE60144376D1 (de) 2011-05-19

Family

ID=22822844

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60144376T Expired - Lifetime DE60144376D1 (de) 2000-07-24 2001-07-24 N und anwendungen

Country Status (8)

Country Link
US (5) US7144918B2 (enExample)
EP (1) EP1303522B1 (enExample)
JP (1) JP4980542B2 (enExample)
AT (1) ATE504589T1 (enExample)
AU (2) AU8083401A (enExample)
CA (1) CA2415611C (enExample)
DE (1) DE60144376D1 (enExample)
WO (1) WO2002008231A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8083401A (en) * 2000-07-24 2002-02-05 Us Health Biologically active macrolides, compositions, and uses thereof
WO2004009079A1 (en) 2002-07-24 2004-01-29 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1000053B1 (en) * 1997-07-25 2004-06-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Macrocyclic lactones, compositions, and methods of use
US7381744B1 (en) 1999-03-05 2008-06-03 The United States Of America As Represented By The Department Of Health And Human Services Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds
AU8083401A (en) * 2000-07-24 2002-02-05 Us Health Biologically active macrolides, compositions, and uses thereof

Also Published As

Publication number Publication date
CA2415611A1 (en) 2002-01-31
JP2004504399A (ja) 2004-02-12
WO2002008231A3 (en) 2002-06-27
US9820965B2 (en) 2017-11-21
US7144918B2 (en) 2006-12-05
US8741947B2 (en) 2014-06-03
ATE504589T1 (de) 2011-04-15
US9139595B2 (en) 2015-09-22
US20150374661A1 (en) 2015-12-31
CA2415611C (en) 2011-03-15
US20060205707A1 (en) 2006-09-14
US20100298248A1 (en) 2010-11-25
US20140243284A1 (en) 2014-08-28
EP1303522A2 (en) 2003-04-23
EP1303522B1 (en) 2011-04-06
AU8083401A (en) 2002-02-05
US20040087566A1 (en) 2004-05-06
WO2002008231A2 (en) 2002-01-31
JP4980542B2 (ja) 2012-07-18
AU2001280834B2 (en) 2006-08-10
US7790764B2 (en) 2010-09-07

Similar Documents

Publication Publication Date Title
PE20020786A1 (es) Derivados de azaindol antiviral
BR9909961A (pt) Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase
ATE176466T1 (de) Furyl-oder thienylcarbonyl-substituierte taxane und diese enthaltende arzneimittel
ATE242634T1 (de) Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums
NL350075I2 (enExample)
MXPA03001072A (es) El uso de bencilidenaminoguanidinas e hidroxiguanidinas como ligandos de receptor de melanocortina.
DE69928567D1 (de) Biodegradierbare polyphosphoester-zusammensetzungen zur behandlung von ovarialkrebs
ES2188194T3 (es) 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4.
PE20061332A1 (es) Derivados de piperidina como agentes inhibidores de la renina
AR012032A1 (es) Compuestos derivados 3'-n-oxido, 3'-n-dimetilamina, 9-oxima eritromicina a y un proceso para su preparacion
NZ314003A (en) Medicaments for treating osteoporosis containing thiazolidine compounds
TW200508274A (en) Antioxidant and bisaminophenol derivative
AR068695A2 (es) Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa
DE60005390D1 (de) Hcv ns3 proteaseinhibitoren
DE60229054D1 (de) Synthese von zyklopentadien derivaten
EP1277744A4 (en) OXADIAZONE DERIVATIVES WITH ANTIBODY EFFECT
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
FI930171A0 (fi) Piperidinfoereningar, framstaellning och anvaendning av dessa
SG146681A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
DE60144376D1 (de) N und anwendungen
AU7623796A (en) Azahexane derivatives as substrate isosters of retroviral asparate proteases
ATE218858T1 (de) C9 taxanderivate und diese enthaltende pharmazeutische zusammensetzungen
MY159418A (en) New derivatives of flavones, their preparation process, their use as medicaments, pharmaceutical compositions and new use